San Diego-based Seqster, a biotech startup announced the release of COVID-19 Compass. The module is built into its tech-enabled platform enabling health care enterprises to track the health of research subjects, in real-time and remotely.

Founded in 2016, the SaaS health care solution seamlessly integrates into any payer, provider, or clinical research enterprise.

The company recently secured an undisclosed amount of investment from Japanese giant Takeda Pharmaceuticals. Prior to the investment, Seqster raised more than $4 million in seed funding.

Patients on the Seqster platform will be able to share key health metrics including body temperature, heart rate and pulse oximetry, synced with devices connected to their Seqster profile.

In addition, patients now can self-report on symptoms of COVID-19 like shortness of breath, fatigue and coughing.

“The spread of COVID-19 is a rapidly evolving situation that can only be effectively monitored with real-time data coming directly from patients themselves,” stated Ardy Arianpour, Seqster’s CEO and Co-Founder. “The need to seek health data instantly has become more critical than ever before. Our COVID-19 Compass is powered by our interoperability technology to enable healthcare enterprises to better navigate the health of their population, while remotely identifying and tracking patients’ symptoms along with vitals collected directly from any connected electronic health record (EHR) or device.”

The COVID-19 Compass module is based on Centers for Disease Control (CDC) guidelines, best clinical practices, among other risk factors.